Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133521 | 0.88 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL2069324 | 0.88 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL2069790 | 0.87 | SMN1; SMN2 (0.61) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL2070396 | 0.82 | MAPT (0.65) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL12055305 | 0.81 | SMN1; SMN2 (0.55) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL29550908 | 0.80 | MAPT (0.73) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL28443416 | 0.80 | MAPT (0.73) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL7498444 | 0.80 | MAPT (0.65) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL2072031 | 0.80 | MAPT (0.65) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 | |
| SCHEMBL329814 | 0.80 | XDH (0.55) | MAPTSMN1; SMN2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526941-A1 | Anti-inflammatory Modalities | Marshall Edwards, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2526941-A1 | Anti-inflammatory Modalities | Marshall Edwards, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| EP-1861090-A1 | ANTI-INFLAMMATORY MODALITIES | Novogen Research Pty. Ltd. (AU) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006108212-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | TNF, PTGES, NFKBIA | MAPT 1933/4885SMN1; SMN2 4339/4885ALDH1A1 2628/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | MAPT 3422/4885SMN1; SMN2 1044/4885ALDH1A1 3385/4885 |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | TNF, PTGES, NFKBIA | MAPT 1933/4885SMN1; SMN2 4339/4885ALDH1A1 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.